Abstract
The Cancer Drugs Fund may allow more patients in England access to clinically effective cancer therapies. In this article oncologists already familiar with the clinical evidence, and experienced in treating with bevacizumab, share practical recommendations on optimal first-line use of this treatment for metastatic colorectal cancer.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols
-
Bevacizumab
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / mortality
-
Colorectal Neoplasms / pathology*
-
Disease-Free Survival
-
Humans
-
Neoplasm Metastasis
-
Randomized Controlled Trials as Topic
-
State Medicine
-
United Kingdom
-
Vascular Endothelial Growth Factor A / immunology
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Vascular Endothelial Growth Factor A
-
Bevacizumab